Resource Type

Journal Article 164

Conference Videos 2

Year

2023 17

2022 21

2021 15

2020 8

2019 9

2018 12

2017 9

2016 5

2015 6

2014 4

2013 5

2012 8

2011 1

2010 5

2009 13

2008 6

2007 8

2006 2

2005 1

1999 2

open ︾

Keywords

immunotherapy 9

COVID-19 4

heterogeneity 4

immune checkpoint inhibitor 4

metastasis 4

tumor 4

PD-L1 3

lung cancer 3

molecular classification 3

Colorectal cancer 2

Exosomes 2

Heterogeneity 2

Immune regulation 2

Nanoparticles 2

Tumor 2

angiogenesis 2

autoimmune 2

cancer therapy 2

genetic modification 2

open ︾

Search scope:

排序： Display mode:

Heterogeneity of the tumor immune microenvironment and clinical interventions

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 617-648 doi: 10.1007/s11684-023-1015-9

Abstract: Heterogeneity of the tumor immune microenvironment and clinical interventions

Keywords： Heterogeneity tumor immune    

HTML PDF Collect

Multi-target combinatory strategy to overcome tumor immune escape

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 208-215 doi: 10.1007/s11684-022-0922-5

Abstract: Immune therapy has become the fourth approach after surgery, chemotherapy, and radiotherapy in cancerMany immune checkpoints were identified in the last decade since ipilimumab, which is the first immuneHowever, fewer people are benefitting from immune checkpoint inhibitor treatment in solid cancers.Along with the characterization of more immune checkpoints, the combinatory treatment of multi-immuneIn this work, the author focuses on the combination therapy of multiple immune checkpoints (does not

Keywords： immune checkpoints     multi-target     immune escape     immune-related adverse events     combination therapy    

HTML PDF Collect

4-1BBL expressed by eukaryotic cells activates immune cells and suppresses the progression of murinetumor

Hui QIU, Hui ZHANG, Zuohua FENG

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 20-25 doi: 10.1007/s11684-009-0006-9

Abstract: The function of 4-1BB/4-1BBL expressed by the immune cells has been the focus for many tumor immunotherapyIn this study, 4-1BBL was expressed in non-immune cells and non-tumor cells, and the role of 4-1BBL inlymphocyte activation and tumor suppression was investigated.the number of CD8 T cells in the peri-tumoral tissue increased markedly, and the growth rate of the tumorThis therapeutic method may provide a promising approach for tumor immunotherapy.

Keywords： 4-1BB ligand     tumor immunotherapy     tumor microenvironment    

HTML PDF Collect

Hyperthermia on skin immune system and its application in the treatment of human papillomavirus-infected

Xinghua Gao, Hongduo Chen

Frontiers of Medicine 2014, Volume 8, Issue 1,   Pages 1-5 doi: 10.1007/s11684-014-0309-3

Abstract: instance, fever-range temperature (39β°C to 40β°C) can modulate the activities of immuneHeat shock temperature (41β°C to 43β°C) can increase the immunogenicity of tumor cellsCytotoxic temperature (>43β°C) can create an antigen source to induce an anti-tumor immune

Keywords： hyperthermia     HPV     immune response     virus     tumor    

HTML PDF Collect

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and

Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 551-561 doi: 10.1007/s11684-020-0760-2

Abstract: Glioma is the most common lethal tumor of the human brain.distinguish the normal brain from other tissues, e.g., the composition of the microenvironment around the tumorSeveral studies correlated tumor recurrence with tumor heterogeneity and the immune microenvironment.In this review, we introduce the different mechanisms involved in glioma progression, including tumorheterogeneity, the tumor microenvironment and drug resistance, and their pre-clinical implements in

Keywords： glioma     evolution mechanism     strategies     tumor heterogeneity     secondary glioma    

HTML PDF Collect

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 726-745 doi: 10.1007/s11684-020-0746-0

Abstract: Mobilization of endogenous immune cells is also necessary for CAR T cells to obtain their optimal therapeuticeffect given the importance of the innate immune responses in the elimination of malignant tumors.this review, we focus on the recent advances in the engineering of CAR T cell therapies to restore the immunecells acting as cellular carriers to deliver immunomodulators to tumors to mobilize the endogenous immunewe discuss the combination of CAR T cells with biomaterials or oncolytic viruses to enhance the anti-tumor

Keywords： CAR T cells     immunoregulatory molecules     endogenous immune response     solid malignancies    

HTML PDF Collect

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 307-321 doi: 10.1007/s11684-022-0927-0

Abstract: The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an importantHowever, immune-related adverse events often occur because of the enhanced immune response enabled byClinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpointStudies have shown that the gut microbiota is essential for the interaction between immune checkpointThis review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an

Keywords： tumor immunotherapy     immune checkpoint inhibitor     antibiotics     gut microbiota     drug–drug interaction    

HTML PDF Collect

Immunometabolism: a new dimension in immunotherapy resistance

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 585-616 doi: 10.1007/s11684-023-1012-z

Abstract: Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionizedthe paradigm of tumor treatment, while substantial patients remain unresponsive or develop resistanceAlthough dysregulated metabolism has long been adjudged as a hallmark of tumor, it is now increasinglyaccepted that metabolic reprogramming is not exclusive to tumor cells but is also characteristic ofimmune response.

Keywords： immune cell     immunometabolism     metabolic reprogramming     immunotherapy     resistance     tumor microenvironment     immune checkpoint inhibitor    

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract: In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overallHere, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpointinhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other

Keywords： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF Collect

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies

Frontiers of Medicine   Pages 805-822 doi: 10.1007/s11684-023-1025-7

Abstract: Immunotherapies based on immune checkpoint blockade (ICB) have significantly improved patient outcomesRecently, numerous studies have revealed that metabolic reprogramming of tumor cells restrains immuneresponses by remodeling the tumor microenvironment (TME) with various products of metabolism, and combination) to influence ICB therapy and propose potential combined immunotherapeutic strategies co-targeting tumormetabolic pathways and immune checkpoints.

Keywords： CTLA-4     PD-1     PD-L1     immune checkpoint blockade (ICB)     metabolic reprogramming     combined tumor therapeutic    

HTML PDF Collect

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 33-42 doi: 10.1007/s11684-019-0735-3

Abstract: Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitorsnon-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-relatedhowever really engrossing issues, such as the association between irAEs and cancer treatment response, tumor

Keywords： cancer     immunotherapy     immune checkpoint inhibitors     immune-related adverse events     review    

HTML PDF Collect

Natural killer cells in liver diseases

Meijuan Zheng, Haoyu Sun, Zhigang Tian

Frontiers of Medicine 2018, Volume 12, Issue 3,   Pages 269-279 doi: 10.1007/s11684-018-0621-4

Abstract: The liver contains a large proportion of natural killer (NK) cells, which exhibit heterogeneity in phenotypicNK cell activation, well known for its role in the immune surveillance against tumor and pathogen-infectedUnder the setting of liver diseases, NK cells are of great importance for stimulating or inhibiting immuneresponses, leading to either immune activation or immune tolerance.

Keywords： natural killer cell     phenotype     immune activation     immune tolerance     liver diseases    

HTML PDF Collect

Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype

Xu Chen, Xiaomao Xu, Fei Xiao

Frontiers of Medicine 2013, Volume 7, Issue 4,   Pages 425-432 doi: 10.1007/s11684-013-0295-x

Abstract: This review briefly describes the heterogeneity of COPD, with focus on recent advances in the correlations

Keywords： chronic obstructive pulmonary disease     heterogeneity     phenotype     genotype     prediction    

HTML PDF Collect

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Tangchun Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 816-819 doi: 10.1007/s11684-020-0823-4

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract: This approach is the first approved tumor treatment using a common biomarker rather than specified tumorMSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immuneresponse in tumor microenvironment, including portions of colorectal and gastric carcinomas.interpreters” or “genetic translators” and build a link between molecular subtypes with tumor

Keywords： molecular classification     precision medicine     pembrolizumab     PD-1/PD-L1     MSI-H    

HTML PDF Collect

Title Author Date Type Operation

Heterogeneity of the tumor immune microenvironment and clinical interventions

Journal Article

Multi-target combinatory strategy to overcome tumor immune escape

Journal Article

4-1BBL expressed by eukaryotic cells activates immune cells and suppresses the progression of murinetumor

Hui QIU, Hui ZHANG, Zuohua FENG

Journal Article

Hyperthermia on skin immune system and its application in the treatment of human papillomavirus-infected

Xinghua Gao, Hongduo Chen

Journal Article

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and

Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang

Journal Article

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Journal Article

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Journal Article

Immunometabolism: a new dimension in immunotherapy resistance

Journal Article

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Journal Article

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies

Journal Article

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Journal Article

Natural killer cells in liver diseases

Meijuan Zheng, Haoyu Sun, Zhigang Tian

Journal Article

Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype

Xu Chen, Xiaomao Xu, Fei Xiao

Journal Article

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Tangchun Wu

Journal Article

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Journal Article